Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Impact BioMedical, Inc. (IBO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: IBO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit 0% | Avg. Invested days 0 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 9.43M USD | Price to earnings Ratio 8.2 | 1Y Target Price - |
Price to earnings Ratio 8.2 | 1Y Target Price - | ||
Volume (30-day avg) 7608898 | Beta - | 52 Weeks Range 0.51 - 6.17 | Updated Date 04/1/2025 |
52 Weeks Range 0.51 - 6.17 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.1 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -4.99% | Return on Equity (TTM) 3.45% |
Valuation
Trailing PE 8.2 | Forward PE - | Enterprise Value 25887012 | Price to Sales(TTM) - |
Enterprise Value 25887012 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 7.28 | Shares Outstanding 11504000 | Shares Floating 5159409 |
Shares Outstanding 11504000 | Shares Floating 5159409 | ||
Percent Insiders 55.16 | Percent Institutions 1.89 |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Impact BioMedical, Inc.
Company Overview
History and Background
Impact BioMedical, Inc. focuses on developing and commercializing innovative therapeutics for cancers and other diseases. Founded with the aim of bringing new treatments to market, the company has made strides in preclinical and clinical research.
Core Business Areas
- Drug Development: Focuses on discovering and developing novel therapeutic candidates, primarily in oncology and virology.
- Clinical Trials: Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
- Licensing and Partnerships: Seeks to out-license its technologies and establish partnerships with other pharmaceutical and biotechnology companies.
Leadership and Structure
The company is led by a team of experienced scientists and business professionals. The organizational structure typically includes departments for research and development, clinical operations, and corporate affairs.
Top Products and Market Share
Key Offerings
- Kpax: A preclinical stage antiviral.
- Equivir: A preclinical stage drug.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high research and development costs, stringent regulatory requirements, and intense competition. Companies are constantly seeking to develop new and improved treatments for a wide range of diseases.
Positioning
Impact BioMedical, Inc. aims to position itself as an innovator in the biotechnology sector, focusing on developing treatments that address unmet medical needs.
Total Addressable Market (TAM)
TAM of pharmaceutical and biotech firms are high. Given that the company is in preclinical and clinical stage, they are positioned well to gain marketshare with successful outcomes.
Upturn SWOT Analysis
Strengths
- Innovative technology platform
- Experienced management team
- Strong pipeline of drug candidates
Weaknesses
- Limited financial resources
- Dependence on external funding
- High risk of clinical trial failures
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Increasing demand for innovative therapies
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Patent expirations
Competitors and Market Share
Key Competitors
- JNJ
- PFE
- MRK
- ABBV
- AMGN
Competitive Landscape
The company's advantage is innovative, but disadvantages include financial resources compared to competitors.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is based on the completion of research and clinical trials.
Future Projections: Future projections depend on the successful commercialization of drug candidates.
Recent Initiatives: Focusing on drug-related research, as well as filing patents.
Summary
Impact BioMedical, Inc. focuses on drug development and clinical trials. It is still a micro cap company with limited finances. Its pipeline of drug candidates has potential, it faces competition from well-established firms. The financial health depends on partnerships, licensing agreements, or successful product launches.
Similar Companies
- JNJ
- PFE
- MRK
- ABBV
- AMGN
- BMY
Sources and Disclaimers
Data Sources:
- Company filings
- Industry reports
- Financial news sources
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered investment advice. The pharmaceutical industry is inherently risky, and past performance is not indicative of future results.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Impact BioMedical, Inc.
Exchange NYSE MKT | Headquaters Houston, TX, United States | ||
IPO Launch date 2024-09-16 | Chairman & CEO Mr. Frank D. Heuszel Esq., J.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 1 | Website https://www.impactbiomedinc.com |
Full time employees 1 | Website https://www.impactbiomedinc.com | ||
Impact BioMedical Inc. focused on discovery, development, and commercialization of products and technologies to address unmet needs in human healthcare and wellness for specialty biopharmaceuticals, antivirals, antimicrobials, consumer healthcare, and wellness products in the United States. The company provides Linebacker, a platform of small molecule electrophilically enhanced polyphenol compounds with application in oncology, inflammatory disorders, and neurology; and Laetose technology that is derived from a unique combination of sugar and inositol, which can inhibit the inflammatory and metabolic response of sugar alone. It also develops functional fragrance formulation, a suite of functional fragrances containing specialized botanical ingredients with application as an antimicrobial, and as an additive in insect repellents, detergents, lotions, shampoo, fabrics, and other substances. In addition, the company develops Equivir/Equivir G technology, a novel blend of polyphenols, which have demonstrated antiviral effects for use in as health supplements and medications. Impact BioMedical Inc. was incorporated in 2018 and is based in Houston, Texas.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.